Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. (PRPO) is a NASDAQ-traded healthcare biotechnology company focused on cancer diagnostics, and its news flow reflects both its operating activities and capital markets developments. The company’s stated mission is to address cancer misdiagnoses through diagnostic products and services that improve accuracy, laboratory workflow, and patient outcomes, and many of its announcements relate to progress toward that mission.
Investors following PRPO news can expect regular updates on the company’s pathology services division and products division. Precipio issues press releases when it files quarterly reports on Form 10-Q, summarizing revenue trends in its diagnostic services and product businesses, gross margin developments, and cash flow metrics. These releases often highlight performance in pathology services and product revenues, along with management commentary on operational efficiency and financial discipline.
Company news also covers product and technology milestones. Precipio has announced developments such as its BCR::ABL1 assay and a joint study with Memorial Sloan Kettering Cancer Center, describing study results, assay performance, and impacts on patient care and laboratory workflows. Additional product-related updates may discuss customer adoption, distributor activity, and the expansion of test panels and applications in customer laboratories.
Capital structure and corporate actions are another recurring theme in PRPO news. The company has issued releases about terminating its at-the-market Sales Agreement with A.G.P./Alliance Global Partners, entering into agreements with warrant holders for cash and cashless exercises, and repaying an advance from Change Healthcare. These updates provide context on share issuance, warrant activity, cash inflows, and the company’s efforts to maintain a clean balance sheet with limited debt.
Precipio also uses news releases to communicate about shareholder update calls, cybersecurity matters, and governance-related events. For example, it has announced quarterly shareholder calls, provided details on a limited-scope unauthorized access incident in its cloud file environment, and requested shareholder participation in voting to achieve quorum at its annual meeting. For investors and analysts, the PRPO news page offers a centralized view of these operational, financial, and corporate developments over time.
Precipio, Inc. (NASDAQ: PRPO) has rescheduled its Q2 2021 update call from August 23 to August 26 at 5:00 PM ET due to a scheduling conflict. Interested participants can access the call by calling 844-695-5519 or registering in advance for a direct dial-in number. The call will allow for pre-submitted questions via email. A replay will be available 24 hours post-call on Precipio's investors page.
Precipio focuses on enhancing diagnostic accuracy through collaborations with esteemed cancer research institutions.
Precipio, a specialty cancer diagnostics company, announced it will host its Q2-2021 update call on August 23, 2021, at 5:00 PM ET. The call will cover key topics concerning its core businesses. A prior communication incorrectly referenced 'year-end' instead of 'Q2-2021 Company Update.' Access to the call can be obtained by dialing 844-695-5519, or pre-registering online for a direct dial-in. Questions can be submitted in advance via email. The company aims to enhance diagnostic accuracy through collaborations with leading academic institutions.
Precipio, Inc. (NASDAQ: PRPO) is scheduled to host its Q2-2021 conference call on August 23, 2021, at 5:00 PM ET. The call will provide updates on the company's core business operations. Interested participants can join via phone or pre-register online for direct access. The call will include a question-and-answer session, and listeners can submit inquiries in advance. A replay of the call will be available on the company's website within 24 hours. Precipio specializes in cancer diagnostics, aiming to improve diagnostic accuracy and reduce misdiagnosis.
Precipio, Inc. (NASDAQ: PRPO) reported a substantial increase in preliminary unaudited revenues for Q2-2021, boasting a 65% year-over-year growth and a 29% increase compared to Q1-2021. This growth is attributed to the company's thriving Pathology services which saw a 60% YoY increase in case volume, and the expanding HemeScreen POL program. The latter has led to a recurring B2B revenue model with commitments from clients for up to four years, boosting operational efficiency and reducing cash burn. The company remains optimistic about continued revenue acceleration throughout the year.
Precipio, Inc. (NASDAQ: PRPO) has terminated its equity line financing with Lincoln Park Capital. The company states that this decision comes as a result of growing revenues, improved gross margins, and a strong cash position, eliminating the anticipated need for further capital raises in the near future. CEO Ilan Danieli expressed gratitude for Lincoln Park's support and noted that the company is now well-positioned for growth without relying on additional funding for at least the next 24 months.
Precipio has launched the HemeScreen® Anemia Panel, a diagnostic tool aimed at identifying molecular genetic errors related to anemia of unknown cause. This rapid blood test assists physicians in detecting potentially fatal acute leukemia, offering same-day results.
The panel addresses a significant clinical challenge, with anemia impacting approximately 1.62 billion people globally. It enhances diagnostic accuracy, potentially increasing revenues for Oncology Physician Office Laboratories (POLs) by 25% based on patient volume.
Precipio, Inc. (PRPO) will host its Q1-2021 corporate update call on May 20, 2021, at 5:00 PM ET, covering updates on core businesses. Participants can join via phone or by pre-registering for a direct dial-in. Questions can be submitted in advance via email. A replay will be accessible 24 hours after the call on the company's Investors page. Precipio aims to reduce misdiagnosis through partnerships with leading institutions like Yale and Harvard, enhancing diagnostic accuracy and patient care standards. For more information, visit www.precipiodx.com.
Precipio (NASDAQ: PRPO) has launched a new Acute Myeloid Leukemia (AML) HemeScreen panel that provides genetic testing results in approximately four hours. This rapid diagnostic test aims to enhance patient care by allowing physicians to select effective treatments swiftly. The AML panel is projected to boost revenues for Oncology Physician Office Laboratories (POLs) by around 10%, depending on patient volume. The introduction of this panel highlights the growing utility of rapid genetic testing in clinical settings.
Precipio, Inc. (NASDAQ: PRPO) announced the launch of its COVID-19 rapid antibody test, now available for POC healthcare providers with an Amazon business account. The test, which detects both IgG and IgM antibodies, received emergency use authorization (EUA) from the FDA and is exclusively distributed on Amazon. This antibody test helps identify those who have developed antibodies post-infection or vaccination, facilitating informed vaccination decisions. CEO Ilan Danieli expressed excitement about the partnership with Nirmidas Biotech and future retail expansion plans.
Precipio reaffirms its forecast that product revenues will reach approximately 50% of pathology revenue by Q4 2021, driven by its HemeScreen POL testing system. Contracted annualized revenues from signed customers currently exceed $750,000 and are expected to rise to $1,000,000. With a pipeline of over 30 prospective customers and the introduction of additional cancer panels, the company anticipates growth in both customer base and revenue. The partnership with ION Solutions is enhancing sales efforts, confirming the product's market acceptance and potential impact on patient care.
FAQ
What is the current stock price of Precipio (PRPO)?
What is the market cap of Precipio (PRPO)?
